SaudiVax
Strategic Partnerships

Tech-Transfer Ecosystem

Global pharmaceutical partnerships integrated through SaudiVax's sovereign manufacturing hub in Jeddah. From biotherapeutics to sterile filling — verified, auditable, compliant.

Network

Global Supply-Chain Integration

Technology transfer partnerships with global pharmaceutical leaders, routed through the Jeddah manufacturing hub.

MRK

Merck KGaA

Biotherapeutics · USA

Technology transfer for monoclonal antibody and recombinant protein manufacturing platforms.

Active since 2023
SVX

SaudiVax

Jeddah Manufacturing Hub

200,000L sovereign biomanufacturing facility. SFDA & FDA aligned. Full tech-transfer integration.

200,000L Total Capacity
OPT

Optima Pharma

Sterile Filling · Germany

State-of-the-art isolator-based aseptic fill-finish technology and equipment partnership.

Active since 2024
SFDA GMP
FDA cGMP Aligned
EMA Annex 1
WHO Prequalification
ISO 14644

Immutable Audit Interface

Zero-trust architecture ensuring absolute data integrity for SFDA submissions and GAMP 5 compliance. Every batch record and deviation is cryptographically hashed and immutable.

Live
Record ID Batch Document Type Timestamp Status SHA-256
BR-2024-00142 SVX-MAB-001-B08 Batch Record Nov 15, 09:23 ✓ Released a7f2c9e3...8b1d
QA-2024-00089 SVX-MAB-001-B08 QA Approval Nov 14, 16:45 ✓ Approved 3e91d4b7...2f6a
DEV-2024-00231 SVX-MAB-001-B08 Deviation Report Nov 13, 11:02 ◉ Resolved 8b4f7a21...c3e8
CC-2024-00067 SVX-VAC-003-A12 Change Control Nov 12, 08:15 ✓ Effective c2e6b19f...a4d7
BR-2024-00141 SVX-VAC-003-A12 Batch Record Nov 11, 14:38 ✓ Released 5d9a8342...e1b9
QA-2024-00088 SVX-VAC-003-A11 QA Approval Nov 10, 10:22 ● Under Review pending
Engagement

Partnership Models

Flexible partnership structures designed to meet your strategic objectives and accelerate your pipeline.

Model A

CDMO Services

Leverage our facilities and expert teams for process development, clinical supply, and commercial-scale biomanufacturing.

Inquire about CDMO
Model B

Strategic Alliances

Collaborate on co-development of novel biologics and vaccines from late-stage research through regulatory approval.

Propose an Alliance
Model C

Technology & Innovation

Engage on technology in-licensing or out-licensing opportunities to accelerate next-generation therapies.

Discuss Technology

Explore Partnership Opportunities

Join our growing ecosystem of global pharmaceutical partners and help build Saudi Arabia's biomanufacturing sovereignty.